Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 27

January 31, 2023 00:38:55
Episode Cover

Episode 27, Part 2: Jamie Heywood, Biotech Engineer and Entrepreneur

"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific Welcome back to Part 2 of our special Few &...

Listen

Episode 35

November 14, 2023 00:44:55
Episode Cover

Episode 35: Charlene Son Rigby, CEO at Global Genes

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...

Listen

Episode 17

January 12, 2022 00:39:58
Episode Cover

Episode 17: Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA)

Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s...

Listen